Show simple item record

dc.contributor.author Molnár, István Artúr
dc.contributor.author Molnár, Béla Ákos
dc.contributor.author Vízkeleti, Laura
dc.contributor.author Fekete, Krisztina
dc.contributor.author Tamás, Judit
dc.contributor.author Deak P
dc.contributor.author Szundi, Csilla
dc.contributor.author Székely, Borbála
dc.contributor.author Moldvay, Judit
dc.contributor.author Vari-Kakas S
dc.contributor.author Szász, Attila Marcell
dc.contributor.author Ács, Balázs
dc.contributor.author Kulka, Janina
dc.contributor.author Tőkés, Anna-Mária
dc.date.accessioned 2017-06-21T12:44:50Z
dc.date.available 2017-06-21T12:44:50Z
dc.date.issued 2017
dc.identifier 85009784396
dc.identifier.citation pagination=275-283; journalVolume=470; journalIssueNumber=3; journalTitle=VIRCHOWS ARCHIV;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/4393
dc.identifier.uri doi:10.1007/s00428-017-2065-7
dc.description.abstract The aim of our retrospective study was to analyze patterns of subtype specific metastatic spread and to identify the time course of distant metastases. A consecutive series of 490 patients with breast cancer who underwent surgery and postoperative treatment at Semmelweis University, Hungary, and diagnosed between the years 2000 and 2007 was identified from the archives of the 2nd Department of Pathology, Hungary. Molecular subtypes were defined based on the 2011 St. Gallen recommendations. Statistical analysis was performed with SPSS Statistics for Windows, Version 22.0. Distant metastasis free survival (DMFS) was defined as the time elapsed between the first pathological diagnosis of the tumor and the first distant metastasis detection. Distant metastases were detected in 124 patients. Mean time to develop metastasis was 29 months (range 0-127 months). The longest DMFS was observed in the Luminal A (LUMA) subtype (mean 39 months) whereas the shortest was seen in the HER2-positive (HER2+) subtype (mean 21 months; p = 0.012). We confirmed that HER2+ tumors carry a higher risk for distant metastases (42.1%). LUMA-associated metastases were found to be solitary in 59% of cases, whereas HER2+ tumors showed multiple metastases in 79.2% of cases. LUMA tumors showed a preference for bone-only metastasis as compared with HER2+ and triple negative breast cancer (TNBC) cases, which exhibited a higher rate of brain metastasis. The most frequent second metastatic sites of hormone receptor (HR) positive tumors were the lung and liver, whereas the brain was the most affected organ in HR-negative (HR-) cases. Tumor subtypes differ in DMFS and in pattern of distant metastases. HER2+ tumors featured the most aggressive clinical course. Further identification of subtype-specific factors influencing prognosis might have an impact on clinical care and decision-making.
dc.relation.ispartof urn:issn:0945-6317
dc.title Breast carcinoma subtypes show different patterns of metastatic behavior
dc.type Journal Article
dc.date.updated 2017-06-08T12:01:37Z
dc.language.rfc3066 en
dc.identifier.mtmt 3177516
dc.identifier.wos 000397952200003
dc.identifier.pubmed 28101678
dc.contributor.department SE/AOK/K/Pulmonológiai Klinika
dc.contributor.department SE/AOK/K/I. Sz. Sebészeti Klinika
dc.contributor.department SE/AOK/I/IISZPI/MTA-SE-NAP B Agymetasztázis Kutatócsoport
dc.contributor.department SE/AOK/I/II. Sz. Patológiai Intézet
dc.contributor.institution Semmelweis Egyetem
dc.mtmt.swordnote István Artúr Molnár and Béla Ákos Molnár equally contributed.


Files in this item

xmlui.dri2xhtml.METS-1.0.onlyFromAllowedIP

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account